Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 1 3Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 245Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 115Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 77Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 62Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 48Melanoma 46Leukemia, Lymphocytic, Chronic, B-Cell 44Carcinoma, Renal Cell 43Stomach Neoplasms 42Urinary Bladder Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Triple Negative Breast Neoplasms 40Brain Neoplasms 40Recurrence 39Myasthenia Gravis 38Small Cell Lung Carcinoma 36Lymphoma, Follicular 35Nasopharyngeal Carcinoma 34Head and Neck Neoplasms 34Pancreatic Neoplasms 32Rectal Neoplasms 30Lymphoma, Large B-Cell, Diffuse 30Colonic Neoplasms 29

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Gemcitabine 1Docetaxel 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Adenocarcinoma, Clear Cell × 1 year × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡